Overview
Anzupgo is approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of moderate to severe chronic hand eczema in adults who have not responded adequately to topical corticosteroids or for whom corticosteroids are not recommended. It should not be used in combination with other Janus kinase (JAK) inhibitors or strong immunosuppressants. Anzupgo is also known by its drug name, delgocitinib.

Anzupgo is a JAK inhibitor. Scientists believe it works by blocking the activity of specific enzymes involved in the body’s immune response, which helps reduce inflammation and itching associated with eczema.

How do I take it?
Prescribing information states that Anzupgo is applied as a cream to the affected areas of the hands and wrists twice daily. It is for topical use only and should not be used in the eyes, mouth, or genitals. The drug should be used exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Anzupgo include application site pain, paresthesia (tingling or numbness), pruritus (itching), erythema (redness), and bacterial skin infections such as finger cellulitis and paronychia (nail bed infection).

Rare but serious side effects may include eczema herpeticum (a viral skin infection), non-melanoma skin cancers such as basal cell carcinoma, and leukopenia and neutropenia (reduced white blood cell counts). There may also be increased risks for serious infections, blood clots (such as deep vein thrombosis and pulmonary embolism), cardiovascular events, and certain cancers. Live vaccines should be avoided during treatment, and lipid levels (cholesterol and triglycerides) may increase.

For more information about this treatment, visit:

Anzupgo (Delgocitinib) Cream, for Topical Use — Leo Pharma